
The opening session of AAO 2026 featured a keynote speech discussing how artificial intelligence (AI) will play a part in health care.
Cell and gene therapies are moving from scientific breakthroughs to real-world treatment options, offering unprecedented potential for patients while creating new challenges for payers, providers, manufacturers and policymakers.
As more therapies enter the market with multimillion-dollar price tags and the promise of long-term clinical benefit, questions surrounding affordability, reimbursement, financial risk and patient access are becoming increasingly urgent.
Managed Healthcare Executive®, The American Journal of Managed Care® and Pharmacy Benefit Management Institute® partnered on this discussion to examine the economic realities shaping the future of cell and gene therapy.






